According to an article published by Foxnews entitled ” FDA approves new oral MS drug, Tecfidera” the following information reveals just how big the market is for NRF2 activating medications and supplements. Tecfidera has been FDA approved to treat just one disease, Multiple Sclerosis. From studies published on Pubmed.gov, NRF2 deficiencies is potentially tied to hundreds of additional diseases and illnesses. The statistics and market impact mentioned in this article is a “drop in the bucket” when it comes to the entire potential for the NRF2 activator industry.
- Biogen is expected to become the largest oral treatment for MS with annual sales exceeding $3-Billion within the next 5 years according to data compiled by Thomson Reuters Cortellis
- Multiple sclerosis affects more than 2.1 million people globally
- The share price of Biogen, producer of Tecfidera have tripled over the past three years upon the hope that this drug would be a big money producer for the company
- There is a huge demand for oral based medication compared to the injected alternatives
- European and US approval of Tecfidera has significantly increased the odds of Biogen meeting its revenue goals
According to Businessweek, “Biogen Idec Inc. (Nasdaq: BIIB) charges $54,900 a year for Tecfidera, its new and promising treatment for multiple sclerosis, and a rival of Teva Pharmaceutical Industries’ (NYSE: TEVA; TASE: TEVA) Copaxone. The US Food and Drug Administration (FDA) approved Tecfidera for sale last week, and analysts believe that it will become the market leader within a few years.”